常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.30/-0.37
|
|
企业价值
289.81M
|
| 资产负债 |
|
每股账面净值
0.29
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
10.00M
|
|
每股收益
0.06
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/19 22:33 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its tworare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). |

1.81 
